Verndari secures BARDA funding for skin patch vaccine

By The Science Advisory Board staff writers

August 27, 2020 -- Biopharmaceutical firm Verndari has secured funding from the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal health agency, to support development of its VaxiPatch microneedle dermal patch vaccine technology.

The funding is administered through BARDA's Division of Research, Innovation, and Ventures (DRIVE), and consists of a $1 million cost-sharing arrangement under which BARDA will provide 68% of the total.

Verndari research scientist Tom Ellison, PhD, shows a close-up sample model of the VaxiPatch at the University of California, Davis Laboratories in Sacramento. Image courtesy of Rudy Meyers Photography.

VaxiPatch is a single-dose vaccination kit that administers vaccines through the skin, according to the firm. It does not require refrigeration. VaxiPatch is currently in preclinical testing at the University of California, Davis, for delivering a vaccine for SARS-CoV-2, Verndari said.

The company is in discussion with the U.S. Food and Drug Administration regarding an investigational new drug submission for VaxiPatch.

Cycle, Medherant partner to develop patch drug delivery
Cycle Pharmaceuticals and Medherant have inked a deal to develop and commercialize multiple medicines using Medherant's Tepi Patch transdermal delivery...
SARS-CoV-2 vaccine utilizing microneedle arrays appears in the literature
Within four weeks of the SARS-CoV-2 spike sequence becoming available, researchers from the University of Pittsburgh School of Medicine developed immunogens...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter